Keywords: Ruholitinib; Acute respiratory distress syndrome; Primary myelofibrosis; Ruxolitinib;
مقالات ISI ترجمه شده Ruholitinib
مقالات ISI Ruholitinib (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Ruholitinib; Janus kinase inhibitor; Myelofibrosis; Pulmonary cryptococcosis; Pulmonary nodules; Ruxolitinib; CT; computed tomography; IL; interleukin; JAK; Janus kinase; TNF; tumor necrosis factor;
Keywords: Ruholitinib; Myelofibrosis; Ruxolitinib; Danazol; Cytopenias;
Keywords: Ruholitinib; Jak inhibitor; Ruxolitinib; SR graft-versus-host disease; SR-GVHD in children;
Keywords: Ruholitinib; JAK; Janus kinase; STAT; signal transducers and activators of transcription; EPOR; erythropoietin receptor; TPOR; thrombopoietin receptor; G-CSFR; granulocyte colony stimulating factor receptor; γc; common gamma chain; SCID; severe combined immunodeficie
Keywords: Ruholitinib; Chronic lymphocytic leukemia; Janus kinases; STAT3; Ruxolitinib; Cholesterol; Lipoproteins; Lysosomal lipase; HMGCR; Nuclear receptors;
Keywords: Ruholitinib; alopecia areata; atopic dermatitis; baricitinib; dermatology; graft versus host disease; JAK inhibitors; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AE; adverse event; CANDLE; chronic atypical neutrophilic de
Keywords: Ruholitinib; Graft-versus-host disease; Intestinal stem cells; Paneth cells; Histone deacetylase; Butyrate; Janus kinase; Ruxolitinib;
Keywords: Ruholitinib; Graft-versus-host disease; Intestinal stem cells; Paneth cells; Histone deacetylase; Butyrate; Janus kinase; Ruxolitinib
Keywords: Ruholitinib; Blast phase; Decitabine; JAK2; Leukemic transformation; Myeloproliferative neoplasm; Ruxolitinib
Keywords: Ruholitinib; JAK1/2 inhibitors; Ruxolitinib; Myelofibrosis; Allogeneic transplantation; Survival
Keywords: Ruholitinib; Anagrelide; Antiplatelet therapy; Essential thrombocythemia; Hydroxyurea; Interferon; Polycythemia vera; Ruxolitinib
Keywords: Ruholitinib; Cytopenias; JAK2 inhibition; Myeloproliferative neoplasms; Ruxolitinib; Splenomegaly;
Keywords: Ruholitinib; Ruxolitinib; Myelofibrosis; Population study;
Keywords: Ruholitinib; Bone marrow fibrosis; Essential thrombocythemia; Polycythemia vera; Primary myelofibrosis; Ruxolitinib
Keywords: Ruholitinib; pierwotna mielofibroza; JAK2; ruksolitynib; Primary myelofibrosis; JAK2; Ruxolitinib;
Keywords: Ruholitinib; BMMCs; bone marrow-derived mast cells; FA; food allergy; JAK; Janus kinase; MCs; mast cells; MMCP; mouse mast cell protease; OVA; ovalbumin; PSA; passive systemic anaphylaxis; STAT; signal transducer and activator of transcription; Tr; regulatory T cell t
Keywords: Ruholitinib; combination therapy; myelofibrosis; ruxolitinib; panobinostat; decitabine; LDE225; PRM-151
Keywords: Ruholitinib; Hepatic inflammation; Ruxolitinib; Janus kinase; Carbon tetrachloride; Oxidative stress; JAK/STAT;
Keywords: Ruholitinib; Myeloproliferative neoplasms (MPN); Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Hematopoietic stem cell transplantation; Ruxolitinib;
Keywords: Ruholitinib; JAK inhibitor; Myeloproliferative neoplasm; Overall survival; Ruxolitinib; Splenomegaly;
1,25-OH2 vitamin D3 and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)
Keywords: Ruholitinib; Calcitriol; MK-2206; Ruxolitinib; Steroid resistance; Jurkat;
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib
Keywords: Ruholitinib; Langerhans cell histiocytosis; Primary myelofibrosis; JAK2; Ruxolitinib; Multilineage myeloid neoplasms; Laser microdissection;
Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death
Keywords: Ruholitinib; Parkinson's disease; mTOR; Jak; Akt; 4E-BP1; Oxidative stress; BSA; bovine serum albumin; CM-H2DCFDA; 5-(and-6)-chloromethyl-2â²,7â²-dichlorofluorescein diacetate; mTOR; mammalian target of rapamycin; MTT; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetr
Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
Keywords: Ruholitinib; Ruxolitinib; JAK; Macrophage; Inflammation; Cytokine;
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
Keywords: Ruholitinib; Signal transducer and activator of transcription 1, gain of function; natural killer cell deficiency; perforin; Janus kinase inhibition; ruxolitinib; natural killer cell maturation; ADCC; Antibody-dependent cellular cytotoxicity; CCD; Coiled-coil domain;
Emerging therapies for atopic dermatitis: JAK inhibitors
Keywords: Ruholitinib; atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
The unique biology and treatment of primary mediastinal B-cell lymphoma
Keywords: Ruholitinib; Anti-PD-1; CD30; Brentuximab vedotin; CHOP; DA-EPOCH; MACOP-B; PD-1; JAK/STAT; Primary mediastinal large B-Cell lymphoma; Pembrolizumab; Radiotherapy; Rituximab; Ruxolitinib; VACOP-B;
SOHO State-of-the-Art Update and Next Questions: MPN
Keywords: Ruholitinib; Essential thrombocythemia; Midostaurin; Myelofibrosis; Myeloproliferative neoplasms; Pacritinib; Polycythemia vera; Prefibrotic; Ruxolitinib;
Research paperRuxolitinib for the management of myelofibrosis: Results of an international physician survey
Keywords: Ruholitinib; Ruxolitinib; Myelofibrosis; Management decisions; Physician survey;
How is the Ph-like signature being incorporated into ALL therapy?
Keywords: Ruholitinib; Acute lymphoblastic leukemia; Philadelphia chromosome-like; tyrosine kinase inhibitor; Janus kinase inhibitor; Imatinib; Dasatinib; Ruxolitinib;
Novedades terapéuticas en tricologÃa
Keywords: Ruholitinib; TricologÃa; Alopecia androgénica; Dutasterida; Alopecia areata; Ruxolitinib; Alopecia frontal fibrosante; VÃa Wnt; Láser de baja potencia; Hair loss treatments; Androgenetic alopecia; Dutasteride; Alopecia areata; Ruxolitinib; Frontal fibrosing alopec
JAK inhibitors in dermatology: The promise of a new drug class
Keywords: Ruholitinib; alopecia areata; atopic dermatitis; baricitinib; JAK inhibitor; JAK-STAT; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AT; alopecia totalis; AU; alopecia universalis; CANDLE; chronic atypical neutrophilic derm
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Keywords: Ruholitinib; JAK; Janus kinase; narrowband ultraviolet B; nbUVB; phototherapy; ruxolitinib; tofacitinib; vitiligo; BSA; body surface area; CXCL9; C-X-C motif chemokine ligand 9; ELISA; enzyme-linked immunosorbent assay; IFN-γ; interferon gamma; JAK; Janus kinase; nbU
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
Keywords: Ruholitinib; JAK-STAT; Myeloproliferative neoplasm; JAK inhibitor; Ruxolitinib; Primary myelofibrosis;
Original ArticleAnti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients
Keywords: Ruholitinib; Multiple myeloma; JAK/STAT; Ruxolitinib; JAK1; JAK2; Small molecule inhibitor;
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
Keywords: Ruholitinib; STAT1 gain of function; IFN-γ; ruxolitinib; autoimmunity; TH1 cell; TH17 cell; follicular T helper cell; T helper cell polarization; ATG; Anti-thymocyte globulin; BSA; Body surface area; GOF; Gain of function; IC50; Half-maximal inhibitory concentration
Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients
Keywords: Ruholitinib; Pediatric systemic lupus erythematosus; Mass cytometry; Monocytes; Cytokines; MCP1; Plasma circulating factors; Type I interferons; JAK inhibition; Ruxolitinib; TLR; Toll like receptor; IC; Immune complexes; JAK/STAT; Janus kinase/Signal transducer and ac
Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?
Keywords: Ruholitinib; Ruxolitinib; Nano-carriers; Alopecia;
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Keywords: Ruholitinib; EGFR; Acquired resistance; Ruxolitinib; Erlotinib; JAK; STAT;
Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation
Keywords: Ruholitinib; STAT1; MPN; CDK8; Kinase inhibitor; Leukemia; Super-enhancer; Cortistatin A; Ruxolitinib;
Inhibidores de JAK2
Keywords: Ruholitinib; Inhibidores de JAK2; Ruxolitinib; Mielofibrosis; Enfermedades autoinmunitarias; ToxicidadJAK2 inhibitors; Ruxolitinib; Myelofibrosis; Immune disorders; Toxicity
Place du ruxolitinib dans la stratégie thérapeutique des syndromes myéloprolifératifs
Keywords: Ruholitinib; Ruxolitinib; Syndromes; myéloprolifératifs; Polyglobulie de Vaquez; Myélofibrose; Thérapies ciblées; Inhibiteurs de JAK2; Ruxolitinib; Myeloproliferative; neoplasms; Polycythemia vera; Myelofibrosis; Targeted therapies; JAK2 inhibitors;
Results from oral gavage carcinogenicity studies of ruxolitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats
Keywords: Ruholitinib; Ruxolitinib; Jakafi; Jakavi; Janus kinase; JAK; Carcinogenicity; Tg.rasH2;
Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity
Keywords: Ruholitinib; Ruxolitinib; Thioacetamide; JAK/STAT; Oxidative stress; Hepatotoxicity;
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma
Keywords: Ruholitinib; Anti-PD-1; Brentuximab vedotin; Fluorodeoxyglucose positron emission tomography; Methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin, prednisone; Primary mediastinal B-cell lymphoma; Radiotherapy; Rituximab; Ruxolitinib;
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Keywords: Ruholitinib; ALL; acute lymphocytic leukemia; AML; acute myelogenous leukemia; AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; HΦ or Φ; hydrophobic; IFN; interferon; IL; interleukin; JAK1/2; Janus kinases 1 and 2; MW; molecular weight; NS
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Keywords: Ruholitinib; Acute myelogenous leukemia; Clinical study; JAK2V617 mutation; Janus kinase inhibitor; Myelofibrosis; Ruxolitinib
SOHO Supplement 2015New Therapeutic Approaches in Polycythemia Vera
Keywords: Ruholitinib; Hydroxyurea; Interferon; JAK2; Polycythemia vera; Ruxolitinib;
Ruksolitynib w leczeniu nowotworów mieloproliferacyjnych Ph(-)
Keywords: Ruholitinib; pierwotna mielofibroza; czerwienica prawdziwa; nadpłytkowość samoistna; nowotwory mieloproliferacyjne; ruksolitynibPrimary myelofibrosis; Polycythemia rubra vera; Essential thrombocytaemia; Myeloproliferative neoplasms; Ruxolitinib